The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

					OMB APPROVAL
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D					OMB 3235- Number: 0076 Estimated average
		Notice of Exempt	Offering of Secu	urities	burden hours per 4.00
					response: 4.00
1. Issuer's Identity					
CIK (Filer I	D Number)	Previous Names	X None		Entity Type
<u>0001626971</u>				X Corporat	ion
Name of	f Issuer			Limited I	Partnership
Corvus Pharmaceutica	als, Inc.			Limited I	Liability Company
Jurisdic				General I	Partnership
Incorporation/	Organization			Business	Trust
DELAWARE				Other (Sp	pecify)
Year of Inco	rporation/Org	anization			
Over Five Years Ag	go				
X Within Last Five Y	ears (Specify Y	ear) 2014			
Yet to Be Formed					
2. Principal Place of B	usiness and Co	ntact Information			
1	Name of Issuer				
Corvus Pharmaceutica	als, Inc.				
S	treet Address 1	L		Street Address 2	
250 GOLDEN HILLS	DRIVE				
City	State/	Province/Country	ZIP/Pos	stalCode Phone Nu	mber of Issuer
PORTOLA VALLEY	CALIFO	ORNIA	94028-7613	650 245 653	35
3. Related Persons					
Last Na	me	Firs	st Name	Middle N	ame
Miller		Richard		А.	
Street Add	ress 1	Street	Address 2		
Corvus Pharmaceutica	als, Inc.	250 Golden Hills	Drive		
City		State/Prov	vince/Country	ZIP/Posta	lCode
Portola Valley		CALIFORNIA		94028-7613	
Relationship: X Exec	cutive Officer X	Director Promot	er		
Clarification of Respo	nse (if Necessar	y):			
Last Na	me	Firs	st Name	Middle N	ame
Gould		Terry		G.	
Street Add	rocc 1	5	Addross 2		

Stree	et Address 1		Street Address 2		
Adams Street Pa	artners, LLC	One No	rth Wacker Drive, Suite 2200		
	City	5	State/Province/Country	Z	IP/PostalCode
Chicago		ILLINC	DIS	60606-2823	
Relationship:	Executive Officer X I	Director	Promoter		

Clarification of Response (if Necessary):

Last Name

Lea

Street Address 1 Corvus Pharmaceuticals, Inc. City Portola Valley Relationship: X Executive Officer Director Promoter

First Name

Leiv

Street Address 2 250 Golden Hills Drive State/Province/Country CALIFORNIA

ZIP/PostalCode 94028-7613

Clarification of Response (if Necessary):

La	st Name	First Name	Middle Name	
Thompson		Peter		
Street	t Address 1	Street Address 2		
OrbiMed Adviso	ors, LLC	601 Lexington Avenue, 54th Floor		
	City	State/Province/Country	ZIP/PostalCode	
New York		NEW YORK	10022-4629	
Relationship: Executive Officer X Director Promoter				
	(10.2.5			

Clarification of Response (if Necessary):

4. Industry Group

Energy Conservation Environmental Services

Oil & Gas

Other Energy

Agriculture		Health Care	Retailing
Banking & Financial Services		Biotechnology	Restaurants
Commercial Banking		Health Insurance	Technology
Insurance		Hospitals & Physicians	Computers
Investing Investment Bank	ing	Pharmaceuticals	Telecommunications
Pooled Investme	nt Fund	X Other Health Care	Other Technology
Is the issuer registered as		Manufacturing	Travel
an investment co the Investment C		Real Estate	Airlines & Airports
Act of 1940?	ompany	Commercial	Lodging & Conventions
Yes	No	Construction	Tourism & Travel Services
Other Banking &	Financial Services	REITS & Finance	Other Travel
Business Services		Residential	Other
Energy		Other Real Estate	
Coal Mining			
Electric Utilities			

5. Issuer Size		
Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000

X Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

6. Federal Exemption(s) and Exclusion(s) Claimed	(select all that a	рргу)			
	Investment (company Act S	Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)		ection 3(c)(9)		
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)	(2) Se	ection 3(c)(10))	
Rule 504 (b)(1)(iii)	Section 3(c)	(3) Se	ection 3(c)(11))	
Rule 505	Section 3(c)	(4) Se	ection 3(c)(12))	
X Rule 506(b) Rule 506(c)	Section 3(c)(5)		ection 3(c)(13))	
Securities Act Section 4(a)(5)	Section 3(c)(6)		ection 3(c)(14))	
	Section 3(c)(7)			
7. Type of Filing					
X New Notice Date of First Sale 2014-11-26 F Amendment	ïrst Sale Yet to	Occur			
8. Duration of Offering					
Does the Issuer intend this offering to last more that	an one year?	Yes X No			
9. Type(s) of Securities Offered (select all that appl	y)				
X Equity		Pooled Inves	tment Fund In	terests	
Debt	hay Cocurity		ommon Securit		
Option, Warrant or Other Right to Acquire Anot Security to be Acquired Upon Exercise of Optio	-	-	perty Securities	5	
X Security to be Acquired Upon Exercise of Optio Other Right to Acquire Security		Other (descri	ide)		
10. Business Combination Transaction					
Is this offering being made in connection with a business combination transaction, such as A Yes X No a merger, acquisition or exchange offer?					
Clarification of Response (if Necessary):					
11. Minimum Investment					
Minimum investment accepted from any outside investor \$0 USD					
12. Sales Compensation					

Recipient		Recipient CRD Number X None	
N/A]	None	
(Associated) Broker or Dealer X None		(Associated) Broker or Dealer CRD N	Number X None
None]	None	
Street Address 1		Street Address 2	
N/A]	N/A	
City	:	State/Province/Country	ZIP/Postal Code
N/A	1	Unknown	00000
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	All States	Foreign/non-US	
CALIFORNIA			

CALIFORNIA
ILLINOIS
NEVADA

NEW YORK

13. Offering and Sales Amounts

Total Offering Amount	\$33,499,965 USD or	Indefinite
Total Amount Sold	\$12,749,982 USD	
Total Remaining to be Sold	\$20,749,983 USD or	Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

12		

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Corvus Pharmaceuticals, Inc.	/s/ Alan C. Mendelson	Alan C. Mendelson	Secretary	2014-12-05

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.